Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF91 (ImmuneEditome ID:7644)

1. Gene summary of enriched editing regions for ZNF91

Gene summary

Gene information	Gene symbol	ZNF91
	Gene ID	7644
	GeneSynonyms	HPF7\|HTF10
	GeneCytomap	19p12
	GeneType	protein-coding
	GeneDescription	zinc finger protein 91\|zinc finger protein 91 (HPF7, HTF10)\|zinc finger protein HPF7\|zinc finger protein HTF10
	GeneModificationdate	20230518
	UniprotID	Q05481;M0QX31;M0R186
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr19:23338761-23339949:-	ENST00000599743.4	ENSG00000167232.12	ZNF91	exonic	AluSz6,AluSc,L1M2	chr19:23338761-23339949:-.alignment
chr19:23341087-23341379:-	ENST00000593341.1	ENSG00000167232.12	ZNF91	ncRNA_intronic	AluSx4,L1P5	chr19:23341087-23341379:-.alignment
chr19:23341087-23341379:-	ENST00000596528.1	ENSG00000167232.12	ZNF91	ncRNA_intronic	AluSx4,L1P5	chr19:23341087-23341379:-.alignment
chr19:23341087-23341379:-	ENST00000596989.1	ENSG00000167232.12	ZNF91	ncRNA_intronic	AluSx4,L1P5	chr19:23341087-23341379:-.alignment
chr19:23341087-23341379:-	ENST00000599281.1	ENSG00000167232.12	ZNF91	ncRNA_intronic	AluSx4,L1P5	chr19:23341087-23341379:-.alignment
chr19:23344184-23344415:-	ENST00000593341.1	ENSG00000167232.12	ZNF91	ncRNA_intronic	AluY	chr19:23344184-23344415:-.alignment
chr19:23344184-23344415:-	ENST00000596528.1	ENSG00000167232.12	ZNF91	ncRNA_intronic	AluY	chr19:23344184-23344415:-.alignment
chr19:23344184-23344415:-	ENST00000596989.1	ENSG00000167232.12	ZNF91	ncRNA_intronic	AluY	chr19:23344184-23344415:-.alignment
chr19:23344184-23344415:-	ENST00000599281.1	ENSG00000167232.12	ZNF91	ncRNA_intronic	AluY	chr19:23344184-23344415:-.alignment
chr19:23359345-23359544:-	ENST00000300619.10	ENSG00000167232.12	ZNF91	exonic	AluY	chr19:23359345-23359544:-.alignment
chr19:23359345-23359544:-	ENST00000397082.2	ENSG00000167232.12	ZNF91	exonic	AluY	chr19:23359345-23359544:-.alignment
chr19:23367041-23368481:-	ENST00000596989.1	ENSG00000167232.12	ZNF91	ncRNA_intronic	AluSx4,AluSg4,AluJr,L1MB2	chr19:23367041-23368481:-.alignment
chr19:23370575-23371332:-	ENST00000596989.1	ENSG00000167232.12	ZNF91	ncRNA_intronic	AluJo,L1MB2,AluSp	chr19:23370575-23371332:-.alignment

Top

2. Tumor-specific enriched editing regions for ZNF91

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr19:23338761-23339949:-	KIRC	EER	3.6211e-02
ENSG00000167232.12,ZNF91	KIRC	EAG	2.1590e-02
chr19:23338761-23339949:-	PRAD	EER	2.2119e-02
ENSG00000167232.12,ZNF91	PRAD	EAG	1.6846e-02
chr19:23338761-23339949:-	UCEC	EER	4.6063e-02
ENSG00000167232.12,ZNF91	UCEC	EAG	3.9570e-02

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr19:23344184-23344415:-	BRCA	Path	EER	1.8514e-02	3.9306e-02	0.2118

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	TypeID	Pkm	Pcox_continuous	HR_continuous	KMPlot
chr19:23338761-23339949:-	MESO	EER	1.0450e-02	3.1593e-02	1.9965e+01
ENSG00000167232.12,ZNF91	MESO	EAG	2.8194e-02	4.6082e-02	1.9253e+01

Top

3. Enriched editing regions and immune related genes for ZNF91

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

4. Enriched editing regions and immune related splicing for ZNF91

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr19:23338761-23339949:-

GBM

EER

ENSG00000160781.11

chr1

156245781:156245795:156245141:156245238:156245141:156245277

-0.3079

3.7951e-02

4.7702e-06

-0.4395

T_cells_CD4_memory_activated

chr19:23338761-23339949:-

GBM

EER

ENSG00000144445.11

chr2

210021422:210023179:210024032:210024201

0.3007

4.5633e-02

1.1549e-05

0.4291

Macrophages_M2

GSVA_HALLMARK_HEME_METABOLISM

chr19:23338761-23339949:-

GBM

EER

ENSG00000125149.7

chr16

67147044:67147094:67147305:67147707

-0.3826

1.2591e-02

6.5000e-06

-0.4050

Plasma_cells

ENSG00000167232.12,ZNF91

GBM

EAG

ENSG00000125149.7

chr16

67147044:67147094:67147305:67147707

-0.3811

1.3948e-02

5.5592e-06

-0.4077

ACIN1;ADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28;LIN28B;MBNL2;MOV10;MSI1;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM47;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184

Plasma_cells

ENSG00000167232.12,ZNF91

TGCT

EAG

MEX

ENSG00000129657.10

chr17

77215922:77215935:77215984:77216101:77216101:77216127:77216153:77216166

0.2420

2.4869e-02

6.1589e-05

0.4300

ACIN1;ADAR;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;MBNL2;MOV10;MSI1;MSI2;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM47;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184

NK_cells_activated

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

ENSG00000167232.12,ZNF91

TGCT

EAG

ENSG00000196670.9

chr5

180847610:180848082:180849153:180849256

0.4029

3.2776e-03

9.9882e-06

0.4007

ADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;MOV10;MSI2;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZNF184

Macrophages_M2

GSVA_HALLMARK_HEDGEHOG_SIGNALING

ENSG00000167232.12,ZNF91

TGCT

EAG

ENSG00000165948.6

chr14

94100738:94100771:94101813:94101975

0.3450

2.4892e-02

1.0715e-06

0.4366

ADAR;AUH;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;MOV10;MSI1;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RBFOX2;RBM10;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184

IFI27L1

Macrophages_M2

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

ENSG00000167232.12,ZNF91

TGCT

EAG

ENSG00000165501.12

chr14

49602369:49602468:49603551:49603618:49607399:49607509

0.2884

1.2812e-02

6.8047e-07

0.4932

ACIN1;AUH;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28A;LIN28B;MOV10;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM47;SAFB2;SLTM;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184

LRR1

Mast_cells_activated

GSVA_HALLMARK_MYC_TARGETS_V2

ENSG00000167232.12,ZNF91

TGCT

EAG

ENSG00000163320.6

chr3

88055413:88057292:88058018:88058223

0.3006

4.0922e-02

1.6205e-05

0.4206

ACIN1;ADAR;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP7;LIN28;LIN28A;LIN28B;MBNL2;MOV10;MSI1;MSI2;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM47;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZC3H7B;ZNF184

T_cells_gamma_delta

GSVA_HALLMARK_DNA_REPAIR

ENSG00000167232.12,ZNF91

TGCT

EAG

MEX

ENSG00000129657.10

chr17

77213917:77215753:77215779:77216101:77216101:77216127:77216153:77216166

0.2489

2.0416e-02

1.6810e-04

0.4086

Mast_cells_activated

GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

More results

Top

5. Enriched editing regions and immune infiltration for ZNF91

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr19:23338761-23339949:-	BLCA	EER	Dendritic_cells_activated	1.9125e-02	0.1644
ENSG00000167232.12,ZNF91	BLCA	EAG	Dendritic_cells_activated	1.6271e-02	0.1653
chr19:23338761-23339949:-	BRCA	EER	T_cells_regulatory_(Tregs)	2.2210e-04	-0.1214
chr19:23344184-23344415:-	BRCA	EER	T_cells_CD4_memory_activated	2.8711e-02	0.2245
chr19:23370575-23371332:-	BRCA	EER	Plasma_cells	2.2637e-04	0.5131
ENSG00000167232.12,ZNF91	BRCA	EAG	T_cells_regulatory_(Tregs)	2.6047e-04	-0.1183
chr19:23338761-23339949:-	CHOL	EER	Macrophages_M0	5.5472e-03	0.5282
ENSG00000167232.12,ZNF91	CHOL	EAG	Macrophages_M0	5.5251e-03	0.5284
chr19:23338761-23339949:-	COAD	EER	Macrophages_M0	2.6439e-02	0.2098
ENSG00000167232.12,ZNF91	COAD	EAG	T_cells_CD4_naive	1.1534e-02	0.2299
chr19:23338761-23339949:-	ESCA	EER	Macrophages_M0	1.9005e-02	0.2428
ENSG00000167232.12,ZNF91	ESCA	EAG	Monocytes	3.0406e-02	0.2065
chr19:23338761-23339949:-	GBM	EER	NK_cells_resting	2.0041e-02	0.2148
ENSG00000167232.12,ZNF91	GBM	EAG	NK_cells_resting	1.6122e-02	0.2220
ENSG00000167232.12,ZNF91	HNSC	EAG	NK_cells_activated	1.3698e-02	-0.3536
chr19:23338761-23339949:-	KICH	EER	B_cells_naive	3.9278e-02	0.2691
chr19:23359345-23359544:-	KIRC	EER	Plasma_cells	3.2314e-03	0.5046
ENSG00000167232.12,ZNF91	KIRC	EAG	Mast_cells_resting	4.9869e-02	-0.1257
chr19:23338761-23339949:-	KIRP	EER	Mast_cells_resting	2.6991e-03	0.2500
ENSG00000167232.12,ZNF91	KIRP	EAG	Mast_cells_resting	1.0546e-03	0.2615
chr19:23338761-23339949:-	LAML	EER	T_cells_CD4_naive	1.4358e-02	0.3587
chr19:23338761-23339949:-	LGG	EER	Mast_cells_activated	4.0638e-04	0.1694
chr19:23359345-23359544:-	LGG	EER	Monocytes	4.3929e-02	0.4062
ENSG00000167232.12,ZNF91	LGG	EAG	Macrophages_M1	3.0993e-04	-0.1678
chr19:23338761-23339949:-	LIHC	EER	T_cells_CD4_naive	2.8199e-02	0.2038
chr19:23338761-23339949:-	LUAD	EER	T_cells_follicular_helper	1.8472e-03	-0.1876
chr19:23341087-23341379:-	LUAD	EER	Monocytes	1.4209e-02	0.2343
ENSG00000167232.12,ZNF91	LUAD	EAG	T_cells_follicular_helper	1.8211e-03	-0.1799
chr19:23338761-23339949:-	LUSC	EER	NK_cells_activated	1.1046e-02	0.1992
chr19:23341087-23341379:-	LUSC	EER	NK_cells_activated	4.8524e-03	0.3505
ENSG00000167232.12,ZNF91	LUSC	EAG	NK_cells_activated	6.5132e-03	0.2044
ENSG00000167232.12,ZNF91	MESO	EAG	Macrophages_M1	4.7999e-02	0.2932
chr19:23338761-23339949:-	OV	EER	T_cells_CD4_naive	2.0072e-02	0.1470
chr19:23359345-23359544:-	OV	EER	B_cells_naive	3.5577e-02	-0.2325
ENSG00000167232.12,ZNF91	OV	EAG	T_cells_CD4_naive	1.8422e-02	0.1461
chr19:23338761-23339949:-	PAAD	EER	Mast_cells_activated	4.6909e-03	0.2955
ENSG00000167232.12,ZNF91	PAAD	EAG	Mast_cells_activated	2.3243e-03	0.3042
chr19:23338761-23339949:-	PCPG	EER	T_cells_CD4_memory_resting	5.4497e-03	0.2533
ENSG00000167232.12,ZNF91	PCPG	EAG	T_cells_CD4_memory_resting	1.5131e-02	0.2152
chr19:23338761-23339949:-	PRAD	EER	T_cells_CD4_memory_resting	3.9658e-02	0.0994
ENSG00000167232.12,ZNF91	PRAD	EAG	T_cells_CD4_memory_resting	2.2074e-02	0.1097
chr19:23338761-23339949:-	SARC	EER	T_cells_gamma_delta	1.3494e-02	-0.2187
ENSG00000167232.12,ZNF91	SARC	EAG	T_cells_gamma_delta	1.7006e-02	-0.2074
chr19:23338761-23339949:-	SKCM	EER	Macrophages_M0	3.0767e-02	0.1888
ENSG00000167232.12,ZNF91	SKCM	EAG	Monocytes	2.3310e-02	-0.1877
chr19:23359345-23359544:-	STAD	EER	T_cells_CD4_memory_activated	1.5855e-02	0.2741
chr19:23367041-23368481:-	STAD	EER	Macrophages_M0	1.3705e-02	0.4018
ENSG00000167232.12,ZNF91	STAD	EAG	T_cells_regulatory_(Tregs)	9.1077e-03	-0.1633
chr19:23338761-23339949:-	TGCT	EER	Macrophages_M2	2.4589e-03	0.2872
ENSG00000167232.12,ZNF91	TGCT	EAG	Macrophages_M2	3.3723e-03	0.2700
chr19:23338761-23339949:-	UCEC	EER	Macrophages_M2	2.4798e-02	-0.2233

Top

6. Enriched editing regions and immune gene sets for ZNF91

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
chr19:23344184-23344415:-	BRCA	EER	1.6849e-03	0.3180	2.2107e-02	0.2346	9.0921e-03	0.2663	4.9774e-02	0.2019

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
ENSG00000167232.12,ZNF91	BLCA	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	1.4592e-02	-0.1679
chr19:23338761-23339949:-	BLCA	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	4.1263e-02	-0.1434
ENSG00000167232.12,ZNF91	BRCA	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	1.8380e-03	0.1010
chr19:23344184-23344415:-	BRCA	GSVA_HALLMARK_MTORC1_SIGNALING	EER	5.8836e-07	0.4862
chr19:23370575-23371332:-	BRCA	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	1.9220e-04	0.5180
chr19:23338761-23339949:-	BRCA	GSVA_HALLMARK_PROTEIN_SECRETION	EER	1.3880e-04	0.1252
ENSG00000167232.12,ZNF91	CESC	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	3.8595e-02	-0.3130
chr19:23338761-23339949:-	ESCA	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	1.7402e-03	-0.3204
ENSG00000167232.12,ZNF91	ESCA	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	6.4766e-05	0.3714
ENSG00000167232.12,ZNF91	GBM	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EAG	9.7048e-04	-0.3011
chr19:23338761-23339949:-	GBM	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	1.7975e-02	-0.2185
ENSG00000167232.12,ZNF91	HNSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.8808e-02	-0.3380
ENSG00000167232.12,ZNF91	KIRC	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EAG	1.3847e-02	-0.1574
chr19:23359345-23359544:-	KIRC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	1.5153e-02	0.4256
chr19:23338761-23339949:-	KIRC	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EER	1.3703e-02	-0.1616
ENSG00000167232.12,ZNF91	KIRP	GSVA_HALLMARK_UV_RESPONSE_UP	EAG	7.0435e-03	-0.2163
chr19:23338761-23339949:-	KIRP	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	4.0275e-02	-0.1723
ENSG00000167232.12,ZNF91	LAML	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	2.6721e-02	0.2988
chr19:23338761-23339949:-	LAML	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EER	2.2444e-02	0.3360
ENSG00000167232.12,ZNF91	LGG	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	9.2282e-10	-0.2810
chr19:23338761-23339949:-	LGG	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EER	6.6301e-08	-0.2562
ENSG00000167232.12,ZNF91	LIHC	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	2.5284e-02	0.2025
chr19:23338761-23339949:-	LIHC	GSVA_HALLMARK_UV_RESPONSE_DN	EER	1.3857e-02	0.2280
ENSG00000167232.12,ZNF91	LUAD	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	2.2618e-04	0.2121
chr19:23338761-23339949:-	LUAD	GSVA_HALLMARK_ANDROGEN_RESPONSE	EER	1.2757e-03	0.1940
chr19:23341087-23341379:-	LUAD	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	1.1152e-05	0.4071
ENSG00000167232.12,ZNF91	LUSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.0135e-02	0.1934
chr19:23338761-23339949:-	LUSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.1113e-02	0.1990
ENSG00000167232.12,ZNF91	MESO	GSVA_HALLMARK_ADIPOGENESIS	EAG	4.4334e-02	-0.2979
chr19:23338761-23339949:-	MESO	GSVA_HALLMARK_G2M_CHECKPOINT	EER	4.8154e-02	0.2962
chr19:23338761-23339949:-	OV	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	2.9942e-02	0.1373
chr19:23359345-23359544:-	OV	GSVA_HALLMARK_GLYCOLYSIS	EER	2.8836e-02	0.2415
chr19:23338761-23339949:-	PAAD	GSVA_HALLMARK_PROTEIN_SECRETION	EER	3.8863e-03	0.3014
ENSG00000167232.12,ZNF91	PAAD	GSVA_HALLMARK_DNA_REPAIR	EAG	1.6674e-02	-0.2413
ENSG00000167232.12,ZNF91	PCPG	GSVA_HALLMARK_KRAS_SIGNALING_DN	EAG	1.5178e-04	-0.3299
chr19:23338761-23339949:-	PCPG	GSVA_HALLMARK_KRAS_SIGNALING_DN	EER	3.9574e-04	-0.3196
ENSG00000167232.12,ZNF91	PRAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.5958e-05	0.2053
chr19:23338761-23339949:-	PRAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	5.3776e-06	0.2176
ENSG00000167232.12,ZNF91	READ	GSVA_HALLMARK_DNA_REPAIR	EAG	1.0815e-02	-0.3685
ENSG00000167232.12,ZNF91	SKCM	GSVA_HALLMARK_P53_PATHWAY	EAG	1.0185e-02	-0.2120
chr19:23338761-23339949:-	SKCM	GSVA_HALLMARK_P53_PATHWAY	EER	3.9607e-02	-0.1801
chr19:23367041-23368481:-	STAD	GSVA_HALLMARK_UV_RESPONSE_DN	EER	3.1407e-02	-0.3544
chr19:23359345-23359544:-	STAD	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	2.2407e-02	0.2600
chr19:23338761-23339949:-	STAD	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EER	2.0593e-02	0.1616
ENSG00000167232.12,ZNF91	STAD	GSVA_HALLMARK_SPERMATOGENESIS	EAG	2.1417e-03	-0.1918
chr19:23338761-23339949:-	TGCT	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EER	9.9639e-05	0.3641
ENSG00000167232.12,ZNF91	TGCT	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	2.3989e-05	0.3814
ENSG00000167232.12,ZNF91	THCA	GSVA_HALLMARK_HYPOXIA	EAG	9.0499e-04	-0.1600
chr19:23338761-23339949:-	THCA	GSVA_HALLMARK_MYOGENESIS	EER	1.7099e-03	-0.1541
chr19:23338761-23339949:-	THYM	GSVA_HALLMARK_PROTEIN_SECRETION	EER	1.6804e-03	0.3688
ENSG00000167232.12,ZNF91	THYM	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	5.1467e-04	0.3890
ENSG00000167232.12,ZNF91	UCEC	GSVA_HALLMARK_SPERMATOGENESIS	EAG	1.7300e-02	-0.2266
chr19:23338761-23339949:-	UCEC	GSVA_HALLMARK_PROTEIN_SECRETION	EER	4.7877e-04	0.3413
ENSG00000167232.12,ZNF91	UCS	GSVA_HALLMARK_DNA_REPAIR	EAG	3.1959e-02	-0.3203
chr19:23338761-23339949:-	UCS	GSVA_HALLMARK_DNA_REPAIR	EER	1.9670e-02	-0.3630

Top

7. Enriched editing regions and drugs for ZNF91

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
ENSG00000167232.12,ZNF91	ACC	Bexarotene	EAG	2.3749e-02	-0.4339
chr19:23338761-23339949:-	ACC	FH535	EER	2.3884e-02	-0.4503
ENSG00000167232.12,ZNF91	BLCA	Bexarotene	EAG	6.9553e-04	0.2317
chr19:23338761-23339949:-	BLCA	Bexarotene	EER	1.9329e-03	0.2164
ENSG00000167232.12,ZNF91	BRCA	A.770041	EAG	2.1828e-06	0.1532
chr19:23344184-23344415:-	BRCA	CCT007093	EER	3.6176e-05	0.4104
chr19:23370575-23371332:-	BRCA	BMS.509744	EER	4.2392e-04	-0.4935
chr19:23338761-23339949:-	BRCA	A.770041	EER	2.0601e-05	0.1400
ENSG00000167232.12,ZNF91	CESC	Dasatinib	EAG	3.7846e-04	-0.5122
chr19:23338761-23339949:-	COAD	GNF.2	EER	3.0950e-02	-0.2040
chr19:23338761-23339949:-	ESCA	Bleomycin	EER	9.4292e-04	-0.3374
ENSG00000167232.12,ZNF91	ESCA	Bleomycin	EAG	4.9260e-09	-0.5221
ENSG00000167232.12,ZNF91	GBM	Dasatinib	EAG	5.0582e-04	0.3166
chr19:23338761-23339949:-	GBM	Dasatinib	EER	5.0529e-03	0.2576
ENSG00000167232.12,ZNF91	HNSC	GW843682X	EAG	5.5612e-04	0.4800
chr19:23359345-23359544:-	KIRC	ABT.263	EER	1.5238e-03	0.5372
ENSG00000167232.12,ZNF91	KIRC	Metformin	EAG	3.0097e-02	0.1389
chr19:23338761-23339949:-	KIRC	IPA.3	EER	8.7220e-03	-0.1718
ENSG00000167232.12,ZNF91	KIRP	JNK.Inhibitor.VIII	EAG	1.4395e-04	-0.3016
chr19:23338761-23339949:-	KIRP	JNK.Inhibitor.VIII	EER	6.9340e-04	-0.2814
ENSG00000167232.12,ZNF91	LAML	KU.55933	EAG	1.7752e-02	-0.3186
chr19:23338761-23339949:-	LAML	JNK.Inhibitor.VIII	EER	2.3210e-02	-0.3342
chr19:23359345-23359544:-	LGG	AG.014699	EER	3.3232e-02	-0.4271
ENSG00000167232.12,ZNF91	LGG	BAY.61.3606	EAG	1.7573e-09	-0.2765
chr19:23338761-23339949:-	LGG	JW.7.52.1	EER	6.4347e-09	0.2747
chr19:23338761-23339949:-	LIHC	FH535	EER	8.6048e-03	0.2429
ENSG00000167232.12,ZNF91	LIHC	FH535	EAG	1.7177e-02	0.2154
chr19:23338761-23339949:-	LUAD	A.770041	EER	4.8659e-02	0.1194
chr19:23341087-23341379:-	LUAD	Epothilone.B	EER	7.7394e-05	0.3694
ENSG00000167232.12,ZNF91	LUSC	AZ628	EAG	1.0984e-02	-0.1913
chr19:23338761-23339949:-	LUSC	FH535	EER	1.1659e-02	0.1977
chr19:23338761-23339949:-	MESO	ABT.263	EER	1.4447e-03	-0.4608
ENSG00000167232.12,ZNF91	MESO	ABT.263	EAG	4.2830e-04	-0.4980
ENSG00000167232.12,ZNF91	OV	CHIR.99021	EAG	2.8720e-03	-0.1842
chr19:23338761-23339949:-	OV	BAY.61.3606	EER	6.2272e-03	-0.1726
chr19:23359345-23359544:-	OV	Bortezomib	EER	3.3551e-05	-0.4411
chr19:23338761-23339949:-	PAAD	BMS.708163	EER	4.8595e-03	-0.2944
ENSG00000167232.12,ZNF91	PAAD	LFM.A13	EAG	4.1240e-03	-0.2873
ENSG00000167232.12,ZNF91	PCPG	BMS.536924	EAG	1.4529e-04	0.3308
chr19:23338761-23339949:-	PCPG	AZD6244	EER	1.9877e-04	0.3347
ENSG00000167232.12,ZNF91	PRAD	BMS.536924	EAG	2.6647e-08	0.2636
chr19:23338761-23339949:-	PRAD	BMS.509744	EER	3.2864e-06	0.2224
ENSG00000167232.12,ZNF91	READ	DMOG	EAG	6.2813e-03	-0.3930
ENSG00000167232.12,ZNF91	SARC	ABT.263	EAG	1.1281e-03	-0.2804
chr19:23338761-23339949:-	SARC	ABT.263	EER	2.1947e-02	-0.2032
ENSG00000167232.12,ZNF91	SKCM	BMS.509744	EAG	2.7589e-03	0.2460
chr19:23338761-23339949:-	SKCM	BMS.509744	EER	6.6860e-03	0.2359
chr19:23367041-23368481:-	STAD	BIRB.0796	EER	4.4398e-02	-0.3324
chr19:23338761-23339949:-	STAD	JNK.9L	EER	3.5074e-02	0.1473
chr19:23359345-23359544:-	STAD	AZ628	EER	4.5722e-03	-0.3199
ENSG00000167232.12,ZNF91	STAD	AG.014699	EAG	1.5193e-03	-0.1980
chr19:23338761-23339949:-	TGCT	BIRB.0796	EER	1.4006e-04	0.3568
ENSG00000167232.12,ZNF91	TGCT	Gefitinib	EAG	7.9372e-05	0.3581
ENSG00000167232.12,ZNF91	THCA	A.770041	EAG	1.7428e-04	0.1807
chr19:23338761-23339949:-	THCA	A.770041	EER	8.5541e-04	0.1636
ENSG00000167232.12,ZNF91	THYM	Embelin	EAG	5.0198e-04	-0.3897
chr19:23341087-23341379:-	THYM	Docetaxel	EER	3.4917e-02	-0.4152
chr19:23338761-23339949:-	THYM	AZD6482	EER	7.0100e-05	-0.4569
ENSG00000167232.12,ZNF91	UCEC	JNK.Inhibitor.VIII	EAG	9.7890e-04	0.3101
chr19:23338761-23339949:-	UCEC	FH535	EER	1.6427e-03	-0.3094
ENSG00000167232.12,ZNF91	UCS	Docetaxel	EAG	1.1879e-02	0.3719
chr19:23338761-23339949:-	UCS	Docetaxel	EER	8.6707e-03	0.4047
ENSG00000167232.12,ZNF91	UVM	EHT.1864	EAG	4.7500e-02	0.4372

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType